Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 1997

View Archived Issues

SKB discloses improved antihyperlipidemic agent

Improved immunomodulating agent described by SKB

Antifungal agents from Nihon Nohyaku

Alcon prepares carbonic anhydrase inhibitors

Antiestrogenics from Schering AG

Boehringer Mannheim reports new antiplatelet agents

Somatostatin receptor antagonists prepared by Novartis

Small, specific inhibitors of VLA4-mediated cell adhesion from Biogen

Antiherpesvirus agent from Roche

Guilford reports 1996 year-end results

NeuroSearch profit announcement in 1996

Neurogen reports 1996 financial results

Genzyme Transgenics reports record fourth-quarter revenues

Genelabs Technologies reports 1996 fourth-quarter and year-end results

Long-acting injectable antifungal enters phase II trials

SS Pharm./Torii developing new antiallergic agent

Zeria and Lilly seek OTC switch for Asinon

Antiparkinson Rx from Sumitomo in pivotal European trials

Pharma Mar product update

Fluticasone associated with more adrenal suppression than budesonide

Cortecs signs oral delivery R&D agreement

Biosite Diagnostics licenses Scios technology

Matrix's radiation enhancer enters phase I/II

Clinical trial results for Neuprex in hepatectomy and meningococcemia

First live oral cholera vaccine approved in Canada

Pharmacopeia achieves milestone in collaboration with Schering-Plough

Banner Pharmacaps granted rights to softgel drug delivery system

Aastrom CPS enters clinical trials in Europe

Neugenesis granted patent for combinatorial biology platform

Visible Genetics and Consolidated Laboratory Services develop HIV tests

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...